Table 1 Patient characteristics
Variable | n (%) mean (SD)* |
|---|---|
Sex | |
Females | 42 (37.5) |
Males | 70 (62.5) |
Age (years) | 62.21 (10.32)* |
BMI (kg/m2) | 26.64 (5.05)* |
CAD | 5 (4.5) |
AH | 45 (40.2) |
Diabetes mellitus | 18 (16.1) |
CCI > 2 | 25 (22.3) |
Alpha blockers | 3 (2.7) |
Beta blockers | 26 (23.2) |
ACEIs | 19 (17) |
Calcium channel blockers | 14 (12.5) |
Diuretics | 10 (8.9) |
ARBs | 9 (8) |
Metformin | 7 (6.2) |
Glimepiride | 7 (6.2) |
Gliclazide | 5 (4.5) |
cT | |
1 | 1 (0.9) |
2 | 10 (8.9) |
3 | 99 (88.4) |
4 | 2 (1.8) |
cN+ | 91 (81.2) |
Distance to the anal verge (cm) | |
0–5 | 42 (37.5) |
6–10 | 52 (46.4) |
11–15 | 18 (16.1) |
Neoadjuvant | |
CRT | 27 (24.1) |
RT | 85 (75.9) |
Time RT-S > 6 weeks | 45 (40.2) |
Loop ileostomy | 23 (20.5) |
ypG | |
1 | 5 (4.5) |
2 | 82 (73.2) |
3 | 8 (7.1) |
x | 17 (15.2) |
ypT | |
0 | 1 (0.9) |
2 | 20 (17.9) |
3 | 91 (81.2) |
TRG | |
0–1 | 27 (24.1) |
2–3 | 85 (75.9) |
Mucinous component | 6 (5.4) |
Tumour deposits | 29 (25.9) |
PLN count | 3.59 (3.75)* |
NLN count | 10.69 (6.16)* |
LNY | 13.99 (6.79)* |
ypN | |
1 | 79 (70.5) |
2 | 33 (29.5) |
LNR | 0.26 (0.21)* |
LODDS | − 1.3 (1.18)* |
ENE | 14 (12.5) |
LVI | 10 (8.9) |
PNI | 13 (11.6) |
Distal margin (cm) | 2.11 (1.61)* |
Adjuvant CT | 89 (79.5) |
Adjuvant CT > 3 cycles | 78 (69.6) |